

16th Annual World Congress on

PEDIATRICS

&

3rd Annual World Congress on

PEDIATRIC NUTRITION, GASTROENTEROLOGY & CHILD DEVELOPMENT

March 21-22, 2018 | New York, USA

ITP, IVIG and I

Kun Soo Lee

Kyungpook National University School of Medicine, Republic of Korea

The main reason for intravenous immunoglobulin G (IVIG) treatment in acute phase of immune thrombocytopenic purpura (ITP) is prevention of possible life-threatening hemorrhage since 1981. On the 1st trial, I just followed the dose of 400 mg/kg/d of IVIG for 5 days for 8 patients with good result in 1983-1984 (*Korean J Pediatr*. 28:483-491, 1985). On the 2nd, I stopped medication when platelet was over 100,000 / μ L for 73 in 1985-1993. Mean treatment days were 2.8 days. The relapse and chronic ITP was less developed in rapid responders (RR: 1-3 treatment days) than in slow responders (SR: more than 3 days) ($P<0.05$) (*Korean J Hematol* 2001;36:241-6). On the 3rd, I also stopped medication when the platelet was over 50,000 / μ L for 68 in 1993-2001. Mean treatment days were 2.9 days. Seven of 28 RR and 6 of 8 SR were chronic type ($p=0.016$) (*Korean J Hematol* 2001;36:247-52). On the 4th, I reduced daily dose to 200 mg/kg/d when the platelet was over 50,000/ μ L for 26 in 2005-2006. Average 2 days treatment were needed to increase the platelet count 50,000/ μ L. Although all 10 non re-treat group who were follow-up over 6 months were acute, all 3 re-treat group who were follow-up over 6 months were chronic ($p<0.003$) (*Clin Pediatr Hematol Oncol* 2006;13:143-9). No one died with 4 studies. The IVIG dose was different according to one's clinical response. In some patient only 1/10 of usual doses (2 g/kg) were sufficient to reach a safe platelet counts in usual life.

Biography

Kun Soo Lee graduated from KNU School of Medicine in 1973, completed pediatric residency in 1978 and received Ph.D. in 1988. He started as an instructor at same KNU in 1981 and retired in 2014. He studied hematology/oncology subspecialty at Division of Pediatric Hematology/Oncology, UCLA, LA, USA. Almost 200 articles have been published. He performed as a President of the Korean Society of Hematology (2002-3), Pediatric Hematology/Oncology (2003-4), BMT (2007), Medical Genetics (2009-11), Pediatrics (2012), internationally Asia Hematology Association (2013-), East Asia Hemophilia Forum (2013), and Advisor of Advanced Neuroblastoma Research Association (2010-). He received a Korea President Award Certificate in 2009.

kslee@knu.ac.kr

Notes: